Best practice with limited resources by Cummings, B. J.
No society has sufficient resources to meet the unbridled
expectations regarding health care of its every member.
Given that resources are limited, how may they be used to
best effect? The answers are many, and depend on the
perspective of the person or group asking the question.
That perspective is subject to personal, political, cultural,
ethical and religious influences. Ideally, the policies and
management guidelines of a national cancer control
programme will be implemented to provide fair and
equitable care to every person in that country [1].
Particularly where there are major limitations in resources
and where universally endorsed policies are lacking, there
is usually a strong element of pragmatism at the level of
delivery. In this essay, the greatest emphasis will be placed
on actions to promote the quality of treatment at the
level of the cancer centre and individual oncologists, for it
is there that most operational decisions are taken and
implemented. This is not to diminish the value of
prevention, screening and non-clinical research, which
are each important elements of a comprehensive national
cancer control programme, but is intended only to focus
discussion.
Determining “best practice”
Declaring a practice to be the “best” implies that it is
better than all others. Rather than assume each patient
has a right to “the best care as available anywhere in the
world”, it is more appropriate to consider the right to
“the best care available within the constraints, fiscal or
otherwise, determined by the society within which
a patient lives” [2]. This is but one example of potential
conflict between collective and individual rights (it
assumes that health care, as well as good health itself, is
a right), and reflects the reality of variations in the
availability of resources. Accepting that constraints are
necessary, it is desirable to consider the standards against
which practice should be measured.
The most appropriate measure of the overall
effectiveness of a cancer control programme is the
national survival rate. Viewed solely by this criterion,
Poland has fared badly in comparisons with other
European countries, although improvements have been
noted over time [3]. When cancer survival rates are
considered together with the relative strength of the
economies of the countries compared, disparities are
more understandable, even if no more desirable. The
challenge is to ensure that the results achieved represent
the best value from the resources available. These points
may be illustrated with data from the EUROCARE
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Study, the World Bank and the World Health Organiza-
tion (WHO).
In the EUROCARE-II Study of adult cancer
patients, it was found that the 5-year relative survival
rates in Poland for all cancers were lower than the
average in Europe [3]. As an example, the survival rates
for breast cancer in various regions in Europe, the
European average, and the comparable rate in the USA
[4], are shown in Table I. While there are several possible
causes for the differences reported, those leading the
EUROCARE project highlighted quality of care, in its
widest sense, as the major determinant for the variation in
the rates. They also noted the potential for cancer survival
rates to interact with the general level of life expectancy
and with socio-economic conditions in each country. Life
expectancy at birth in Poland rose from about 71 years in
1978 to about 73 years in 2000, but remained consistently
3 to 5 years less than in other countries which participated
in EUROCARE-II. In 2001, the World Bank ranked
Poland 74th of 205 countries in its list of Gross National
Income (GNI) per capita, the lowest of the EURO-
CARE-II participants [5]. The dangers of “ranking-
tables” are well-known, and these observations alone do
not establish whether the care received by cancer patients
in Poland was the best possible with the resources
available at the time of the EUROCARE reviews.
However, commentators in Poland have remarked on
delays in diagnosis and other factors as major contributors
to poor cancer survival rates [6, 7]. The improvement in
the survival rates for breast cancer seen over the two
periods shown in Table 1 presumably resulted at least in
part from successful efforts to promote both earlier
diagnosis and the broader application of effective
treatments.
One indicator often used to compare national
expenditures on health care is the percentage of GNI
committed to this purpose. In Europe, this percentage is
usually in the range of 6% to 10%, with Poland lying at
the lower end of that range (1998 figures) [8]. More
revealing is a comparison of the international dollar value
of annual per capita expenditures for health care
(Table 1). The range then is seen to be much greater,
with most European countries expending between $1500
and $2400 per capita, but with Eastern European
countries considerably less, between about $500 to $900
(some countries in WHO list are not shown in table). All
European countries lie substantially below the $4000 per
capita expended on health care in the USA. Yet it is
common for countries to expect to match the health care
outcomes achieved in the USA with its much greater
resources. A more realistic short-term target for Eastern
Europe would seem to be to apply their more limited
resources to match, through the adoption of best
practices, the results achieved in regions of Europe able to
commit only moderately greater financial resources to
health care.
Shortage of physical resources contributes to
difficulties in making effective treatments readily available
to all who might benefit from them. While it may not be
easy to estimate the extent of shortages of multipurpose
resources, such as surgical facilities, single purpose
resources, such as radiation treatment equipment and
staff, are easier to assess [9, 10]. Figure 1 shows data from
the International Atomic Energy Agency (IAEA) for the
Table I. Trends in Survival for Breast Cancer by Region and Economic Indicators
Regiona 5y Relative Survival Countries in Regiona Total Expenditure Per Capita Total 
Rate (%)a on Health as % of GNI Expenditure on Health 
(1998)b in International Dollars
(1998)b
1978-80 1987-89
Northern Europe 75 81 Finland 6.9 1570
Sweden 7.9 1731
Iceland 8.4 2277
Denmark and United Kingdom 63 68 Denmark 8.3 2138
England and Scotland 6.8 1512





Eastern Europe 31 56 Estonia 6.0 516
Poland 6.4 535
Europe (Weighted average) 65 74
United States 75c 81c USA 12.9 4055
a Regions and Countries, Survival Rates for Europe from Sant el al [3]
b Economic data from World Health Organization [8]
c United States data for 1977-79 and 1983-90 from SEER [4]
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number of megavoltage radiation treatment machines
per million population, and relates this to per capita
GNI [10]. At the time of the survey, Poland had 54 such
machines, less than 2 machines per million, and well
below the 6 per million estimated to be appropriate to
fully realize the contribution this modality can make to
cancer control [11]. It can be seen that relatively few
countries have reached the recommended level. It was
estimated that around 1990, no more than about 12% of
cancer patients in Poland received radiation treatment
[7], compared with the planning target of 45% to 55%
adopted, but not always achieved, in many other countries
[12]. The proportion of patients treated by radiation in
Poland now is estimated to be about 30% (B. Macie-
jewski, personal communication 2002). As in many
countries, the shortage of physical resources has been
partially overcome by operating equipment for extended
hours each day.
Additional funds are generally needed if a limited
resource pool is to be enlarged, although some
redistribution of existing funding may be possible.
Redistribution of funding within healthcare systems is
often constrained, particularly when funds are limited,
and interest groups defend existing allocations fiercely
[13]. However, relatively small (percentage-wise) real-
locations of funding may offer potentially significant
improvements in cancer treatment. The proportion of
health care expenditures allocated to cancer treatment
ranges from about 6% to 15%, with Poland and Eastern
Europe in the lower bracket and the USA at the upper
limit [14]. Analyses in Sweden over the past decade
showed that the direct costs of radiation treatment were
only about 5% of the national expenditures for cancer
treatment (at a time when it was estimated that about
30% of those who could benefit from such treatment
actually received radiation), and the cost of cytotoxic
drugs was also about 5% (the costs of administering this
form of treatment were not included, as they were for
radiation therapy, and many expensive drugs which
have recently come on the market were not in use at the
time of this survey) [15, 16]. About 40% of the costs of
cancer treatment in Sweden were consumed by inpatient
surgical care, and 10% by drugs other than cytotoxic
agents. It may be assumed that much of the remaining
expenditure was for palliative and terminal care [17]. It is
not possible here to expand on the possibilities for
reallocation of funding for cancer care since this would
require detailed knowledge of national and local planning
priorities.
Issues in resource allocation
Consideration of the ethics and practice of resource
allocation in health care commonly takes place informally
at the level of individual oncologists, with policy makers
seemingly reluctant to engage in debate. Limited resources
force choices. If choices are not formally planned, then
each cancer centre and oncologist “does his best”, usually
without considering the effects of their actions on society
as a whole, and restrictions in utilization arise in an ad hoc
fashion. However, experts in the philosophical, ethical
and economic aspects of resource allocation for health
Figure 1. The number of megavoltage radiation treatment machines by global region related to Gross National Income per capita ($US). Log-Log plot.
Adapted from Levin et al [10].
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care are increasingly participating in, and informing,
discussion [18-21].
The merits of any medical intervention are usually
assessed in terms of clinical effectiveness [22]. To the
most important, and commonly used, endpoint of survival
has recently been added quality of life. This latter
measure has relevance for all treatments, but may be
particularly useful for treatments of advanced or meta-
static cancer which may not improve survival. Surrogates
for, or alternatives to, survival must be chosen carefully, as
some may be misleading, especially to patients who lack
the depth of understanding of the oncologist. One such
alternative end-point is “response”, often misinterpreted
by patients and their families as correlating with cure,
which is not always true. Such confusion may be compo-
unded by the presentation of possible outcomes in relative
rather than absolute terms. As an extreme example, the
improvement in survival rate with a new treatment may be
described as “50%”, but in absolute terms represent an
increase from as little as 2% to only 3%. In some
societies, there is often reluctance among physicians,
patients and their families to discuss the diagnosis of
cancer, the treatments available, and the prognosis,
especially when the patient has advanced cancer [23, 24].
Physicians have an ethical obligation to present
potential benefits and disadvantages fairly and clearly to
patients. Best practice requires a balance on the part of
the oncologist between stark directness and unreasonable
paternalism. When the results of available interventions
are known to be poor, there is great pressure to explore
new technologies and treatments, often heralded in both
the medical and lay press as “promising” or “potential
breakthroughs”. Real benefits from many new treatments
are often limited however [25, 26]. For example, in a 10
year review of abstracts reporting randomized trials of
treatments for advanced breast cancer published by the
American Society of Clinical Oncology, only 3 of 142
described an improvement in survival from experimental
treatment which reached statistical significance (p<0.05)
[26]. Discussion of the relationships of clinical and
statistical significance is beyond the scope of this
presentation, but it must be noted that many patients
regard even very small increases in survival as worth
pursuing [22]. Assessment of quality-of-life now plays
a greater role in determining the benefit of new
interventions, and attempts to assay the impact of cancer
and its treatment on the physical, psychological and social
components of a patient's life [22]. While physicians
generally understand a result presented in terms of the
duration of symptom-free survival, many remain less
comfortable with the methodologies of the social sciences
used in some quality-of-life assessments, and are often
resistant to the application of the utilities inherent in the
computation of such measures as “quality adjusted life
years” (QALYs) [27].
It has been suggested that to the evaluation of
clinical effectiveness be added an assessment of cost
effectiveness, and that this should include not only the
effect on the patient who received the medical care in
question, but also that on other patients in the health
care system who did not receive benefits they could have
obtained had those resources not been otherwise
used [28]. While this latter economic concept (called
opportunity cost) is used infrequently, many clinical trials
now include some form of cost analysis, if not true cost
effectiveness assessment [20]. It should be remembered
that, just as the apparent clinical effectiveness of an
intervention may not be generalizable from the setting
in which it was conducted (often a clinical trial in which
patients had carefully defined characteristics, including
good performance status), differences in health care
systems may mean that cost analyses also cannot be
generalized. In economically advantaged communities,
the efficacy of an intervention usually outweighs cost
effectiveness considerations, and these may be further
distorted where a private payer system exists. In countries
with markedly limited resources, however, rational
choices may be facilitated by informed and relevant cost
effectiveness analyses (although appropriately trained
health economists to perform such analyses may be
among the resources in short supply).
The efficient use of resources may require operation
of facilities and equipment during “unfashionable” hours,
and extended operation of high cost equipment is
common, where there are sufficient trained personnel.
It is often more efficient to purchase commercial
packages incorporating tested equipment, rather than
committing the time of scarce personnel to the develop-
ment of new systems. Exceptions to this may occur where
observation of commercial systems suggests alternative
and substantially cheaper ways of achieving the same
result, and considerable ingenuity is often demonstrated
to circumvent resource limitations.
The development of appropriate collective respon-
sibility for the ethical distribution of limited resources is
rarely addressed. Decisions are often left by government
and its bureaucracy, which seek to avoid political
unpopularity, and the public, who are usually not
consulted formally and may be poorly informed of the
issues, to physicians, who are assumed to have the
requisite knowledge to prioritize the use of resources.
However, it has been argued that only a collective
solution, to which the larger population subscribe, can
resolve the conflict between the ethical responsibilities
of physicians to offer the best available medical care to
the patients for whom they have assumed responsibility,
and their role as gatekeepers of the limited health care
resources available for all patients collectively [29]. Wide
public consultation, such as that carried out in Oregon,
USA, to prioritize medical services for funding, has not
been attempted elsewhere [30]. Some countries, for
example, England and Wales, have introduced processes
to involve patients and the public in developing and
evaluating policy and practice [31]. More often however,
public involvement in the determination of resource
allocation is manifest through special interest groups,
who usually advocate the commitment of additional
resources to management or research of a specific cancer
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type rather than address the needs of the community as
a whole.
Best practice and the cancer centre
In the following section, several measures intended to
promote best practice at the level of a cancer centre are
discussed briefly. Most are applicable whether or not
resources are limited.
P l a n n i n g
While some form of organizational planning to meet
short-term needs is common, the more important longer
term strategic planning is often neglected. Failure to
communicate goals and objectives contributes greatly to
fragmentation of effort and the frustration of staff and
patients. Planning should be realistic, and objectives
should not run so far ahead of provision of the resources
necessary that the planning process is discredited.
D a t a  c o l l e c t i o n  a n d  a n a l y s i s
Effective assessment of resource utilization and mana-
gement is not possible without adequate up-to-date data.
Even when funding is limited, it is essential that sufficient
resources be committed to collecting and reviewing key
indices. It is surprising how frequently, even in major
cancer centres with substantial budgets, data on such
basic features as the number of patients seen and treated,
waiting times, cancer diagnosis and stage, and outcome
are either not available or are accessible only by retro-
spective review. Only prospective data collection and
contemporary review can allow timely response to
important changes. An example of failure to perceive
predictable changes in the demand for resources, and to
examine in a timely way data available in a comprehensive
prospective electronic register, occurred in Ontario,
Canada, between about 1984 and 1992. During that
period, waiting times for radiation treatment increased
dramatically. Retrospective analysis of the registry data
some years later showed that changes in utilization
patterns could have been identified, and efforts made to
obtain additional resources, much earlier than actually
occurred [32]. Three major demands for increased
utilization of radiation therapy were found, beyond those
expected from annual increases in the incidence of cancer:
the adoption of lumpectomy and postoperative radiation
as the preferred treatment for early stage breast cancer;
more widespread use of adjuvant radiation for rectal
cancer; and the introduction of PSA testing which iden-
tified many early stage prostate cancer patients who were
referred for radiation therapy. The analysis also revealed
that during the same period there were reductions in
the use of radiation treatment for conditions such as
gynecologic, lung, and head and neck cancer and for
palliation, for which no good medical reasons could be
identified.
Wa i t i n g  l i s t s
One of the first manifestations of an imbalance between
resources and demand is a waiting list. Waiting times
should be assessed against standards which are formalized
and transparent. Those standards should be set by expert
assessment of available biological and clinical data.
Typical standards are those adopted in the UK [33] and in
Canada [34]. The radiation oncology specialty bodies in
those countries recommend consultation be provided
within 2 weeks of a request, and that treatment commence
within 2 weeks of a decision to treat (in non-emergency
cases). The standards provide a measure by which resour-
ces meet an ideal, and should not be changed (for
example, in response to political pressure) to reflect the
resources actually available. A “shorter” waiting list may
be politically desirable, but if the number of patients on
the list is reduced by adopting medically inappropriate
permissible delays, such changes in the standard for
waiting times will eventually contribute to poor clinical
outcome.
As physicians in a community become aware that
waiting times for cancer treatment are lengthening, they
often apply ad hoc rationing, and may make decisions
which would not be made by oncologists. Review of the
Ontario data referred to earlier identified such ad hoc
rationing on the basis of increasing patient age; the
distance of a patient's residence from a cancer centre;
the intent of treatment, with under-referral particularly
for palliative or adjuvant radiation treatment; and lower
patient socio-economic status [32, 35]. It is likely that
additional reasons were present but not identified. It is
also probable that similar patterns of ad hoc rationing
occur wherever resources are limited.
When there are delays before a preferred inter-
vention can be offered, there is great pressure for
physicians “to do something”. Particularly where there
are delays in oncologic surgery or radiation therapy, this
has led to widespread use of neo-adjuvant chemotherapy.
Because this treatment is largely unproven, and is not
delivered in the formalized context of a clinical trial, it is
difficult to determine whether the practice is advanta-
geous. Randomized trials of neoadjuvant therapy have
produced mixed results so that generalization is not
possible. Some laboratory studies indicate that any partial
treatment, be it surgical, radiotherapeutic or cytotoxic
drug, may stimulate the growth rate of residual cancer,
and thus jeopardize the outcome of definitive treatment
when it is eventually given. Unattractive though the
concept is, when delays prevent timely management by
established therapies, an alternative equally effective
(for cure or palliation) but less desirable (for organ
conservation or for side effects) definitive treatment may
be best practice.
C l i n i c a l  p r a c t i c e  g u i d e l i n e s
Every physician generally has an approach to the treat-
ment of each cancer patient for whom he is responsible
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which he regards as “standard”. This “standard” treat-
ment is often based only loosely on best evidence. In one
study of the diversity of treatments recommended for
defined clinical scenarios, oncologists offered as
the basis for their recommendations local policies,
logistical constraints, training and experience, and patient
convenience. Fewer than 10% alluded to current or
previous clinical trial results [36].
Determining whether local policies, applied by an
individual or a group of physicians, are “best” clinical
practice requires comparison with external standards.
Efforts to identify the most scientifically sound and useful
information from amongst the vast volume of published
reports have led to the promotion of the evidence-based
medicine and clinical practice guideline initiatives. The
intent of guidelines is to promote consistency of care,
and the use of the most clinically effective interventions,
thus reducing the often somewhat arbitrary value jud-
gements which are a characteristic of individual medical
practice [2]. The publication of clinical practice guidelines
does not ensure their adoption, but they offer physicians
a standard against which to measure the care they offer
[37]. The effect of guidelines on practice is often modest,
although it generally increases with time. There is no
agreement on what level of compliance with a guideline in
a community is appropriate, and wide variations are
reported.
While guidelines promote clinical effectiveness and
efficiency, they often do not address cost effectiveness.
Although published guidelines and evidence-based
medicine reviews offer the physician short cuts through
the mass of published data, it is essential that each guide-
line be reviewed, and if necessary modified, by those in
any cancer centre in which it is proposed the guideline be
implemented. Many are first written by physicians in
relatively resource-rich settings, so that recommendations
that depend on the ready availability of sophisticated
technology, for example, may not be practical. Nor are all
published guidelines and evidence-based reviews free of
scientific error or of conclusions not justified by the data
[38, 39]. Where relevant external guidelines are not
available, consistency of care and efficient use of resour-
ces should be fostered by the development of local
consensus.
Au d i t  a n d  q u a l i t y  a s s u r a n c e
When resources are limited, particularly when patient to
physician ratios are excessive, it is all too easy to omit
audit and quality assurance procedures in the search for
“more time”. Yet these procedures can greatly improve
the level of care and should be considered an essential
element of best practice. Audit has been described as
“the systematic critical analysis of the quality of medical
care, including the procedures used for diagnosis and
treatment, the use of resources and the resulting outcome
and quality of life for the patients” [40]. This rather
daunting all-encompassing definition is applicable in all
settings, even when resources are limited. Audit can be
applied to small, selected segments of practice, in
successive projects which can be integrated to form an
overview of a whole process, and identify areas which
can be improved. For example, radiation oncologists in
a small regional cancer centre worked either as a full
group or as subgroups to audit 3052 radiation treatment
plans (about half of all plans prepared) over an 8-year
period, using predetermined criteria. Changes were
recommended in 4.1% due to apparent errors in radiation
planning, and a further 3.6% were found to deviate from
previously agreed treatment policies [41]. Where these
reviews were performed before treatment started, they
served to improve quality further by enabling amendment
of the plans. Similarly, a two-week study in 2001 in a large
cancer centre disclosed errors or omissions in 15% of
940 drug prescriptions (unpublished).
Participation in multicentre collaborative clinical
trials, such as those conducted by the EORTC (European
Organization for the Research and Treatment of Cancer)
offer an important means of improving the quality of
care. Even in a resource limited centre, the efforts
expended to collect the data required for such trials are
more than offset by the advantages of assessment and
advice from the sponsoring organization's quality review
processes. For example, in an EORTC randomized trial of
radiotherapy for patients with Stage I or II breast cancer,
a quality assurance program was implemented to confirm
that breast irradiation was carried out in a standard
fashion in all centres. A team of physicists verified the
calibration of the radiation beams in the participating
centres, and a programme was set up for comparing the
calculated doses and the doses delivered, together with
a process to identify the reasons for any discrepancy [42].
Even quite small variations in the dose of radiation
delivered may have significant effects on the rates
of cancer control and normal tissue toxicity [43]. The
importance of repeated audits, the need for additional
physicists with appropriate training in clinical radiation
therapy, and for replacement of obsolete treatment
machines and dosimeters were emphasized in a study
by the European Radiation Oncology Programme
for Assurance of Treatment Quality (EROPAQ) in which
47 (94%) of the radiotherapy centres in Poland, the
Czech Republic and Hungary participated [44]. Among
the 22 centres which had not participated in external
audit previously, only 68% of the treatment beams
checked were calibrated correctly (within ± 5% of the
intended dose delivered), compared to 84% in treatment
centres which had participated in an earlier audit at least
once.
N e w  t e c h n o l o g y  a n d  d r u g s
Although several frameworks incorporating assessment of
clinical and cost effectiveness have been proposed for
the evaluation of new, and established, technology and
treatments [20, 45, 46], it is not apparent that such
processes are used consistently. Paradoxically, expendi-
tures on treatments already in use, and therefore deemed
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to be “approved”, whether or not they were ever formally
assessed prior to their introduction, are subjected to
critical review only infrequently. Expenditures on
“approved” treatments may vary widely between centres,
reflecting the lack of generally accepted treatment
guidelines, and affecting the funding available for other
requirements. For example, in three Canadian cancer
centres, to each of which about 2500 patients were
referred in a year for consideration of cytotoxic chemo-
therapy, the proportion of patients who received
intravenous chemotherapy varied from 60% to 98%, and
the total costs for this treatment ranged from about $6
million to $9 million Can (unpublished).
Introduction of new and expensive drugs and
technology represents one of the most serious stresses
on resources, and can be achieved fairly and rationally
only where there are effective systems in place to analyze
the merits and costs of all treatments, new and old, and
where there is reasonable agreement on how priorities
should be set and resources allocated.
I m p r o v i n g  e f f i c i e n c y  a n d  e f f e c t i v e n e s s
Reappraisal of existing treatment practices, training of
staff in new and superior techniques, and review of the
traditional roles of staff are examples of actions which
may each result in improved efficiency and effectiveness
without increased resources.
The retrospective audits of the use of radiation
treatment in Ontario noted earlier (32)led to prospective
research which has significant resource implications. In
one study, 551 patients with node-negative breast cancer
who had undergone lumpectomy and axillary dissection
were found to have received adjuvant breast irradiation
according to 48 different radiotherapy schedules,
reflecting the lack of agreed guidelines [47]. In a sub-
sequent prospective trial, in a similar patient group,
women were randomly assigned to receive whole breast
irradiation by 16 treatments in 22 days or 25 treatments in
35 days [48]. With a median follow-up of 69 months, the
5-year local recurrence-free survival rates were 97.2%
(short course) and 96.8% (long course). No differences
were detected in disease-free or overall survival rates,
and the percentages of patients with an excellent or good
global cosmetic outcome at 5 years were 76.8% and
77.4%. Thus, equivalent results were achieved using only
65% of the radiation therapy capacity required by the
longer treatment schedule.
There has been a substantial reduction in the risk
of pelvic recurrence following resection of cancers of the
rectum by adoption of techniques of wide sharp dissec-
tion, sometimes referred to as total mesorectal excision,
and by special procedures for the examination of the
tissues removed. In several countries, these techniques
have been taught in special surgical and pathology work-
shops and by mentoring, and have not required the
training of additional surgeons or pathologists. For
example, the rate of pelvic recurrence at 5 years was
reduced from 15% to 8%, and the rate of cancer-related
death also improved, following workshops conducted in
Stockholm [49].
Where there are shortfalls in the numbers of staff
required to support a certain function, it is helpful
to determine whether activities, traditionally the respon-
sibility of one profession, can be delegated or transferred
to others. For example, throughout much of the world
many of the technical aspects of radiation treatment
planning have been transferred from clinical physicists
to radiographers. Nurses and radiographers have also
assumed responsibility for some patient assessment and
follow-up activities. Detailed advice on such transfer of
responsibilities has been offered by the UK Royal College
of Radiologists [50].
C o n s e r v i n g  r e s o u r c e s
Conserving existing resources, particularly trained
personnel, is an important element of “best practice”.
Where there is a significant imbalance in the clinical
demands on a profession, there is increased risk of
burnout, further reduction in the workforce available,
and difficulty in recruitment. A study in the UK of four
medical specialist groups, including oncologists, identified
insufficient resources among the factors associated with
both burnout and psychiatric morbidity among physicians
[51]. Management of this type of imbalance is difficult,
but efforts should be made to ensure clinical and other
types of work are distributed fairly. Additional respon-
sibilities, such as teaching and administration, should be
reviewed regularly. The introduction of new technologies
and treatments may place additional loads on some staff,
and clinical productivity may decrease temporarily while
staff become familiar with new techniques. Active
management is necessary to maintain individual work-
loads at tolerable levels.
It is sometimes assumed, incorrectly, that limited
resources prevent research and development program-
mes, and that all available resources should be committed
to providing proven methods of care. However, a defined
portion of resources should be reserved for a coherent
focussed plan of research, principally in academically
linked centres. This permits the fostering of ambition
and excellence and helps the retention of staff. There is
no reason why a country or cancer centre with limited
resources should not aspire to, and achieve or surpass, the
levels of excellence of better economically endowed
countries – they should not, however, attempt to match
the breadth of research in those countries.
Conclusion
Pursuit of a coherent programme, which supports best
practice and optimum use of limited resources, is
especially difficult at a time when the world is experienc-
ing unprecedented biomolecular and technological
development. The tenets of best practice are based on
the promotion of appropriate ethical and professional
relationships, proper evaluation of the clinical and cost-
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effectiveness of whatever treatments and technologies
are available within the constraints imposed by the
community, the use of evidence-based clinical practice
guidelines, and efforts to fully involve the public,
government, patients and physicians in seeking a common
resolution to issues of resource allocation.
Professor B. J. Cummings
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610 University Avenue
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